John Barbetseas

John Barbetseas

Auto-generated profile, based on publicly available information

John Barbetseas

Department of Cardiology, Laiko General Hospital, 11527 Athens, Greece

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 January 2012 in Virology Journal
Verified
Journal Article
Open access
PDF file
PDPanagiotis Theodorou Diamantopoulos
Panagiotis Theodorou Diamantopoulos
MMMaria Michael
Maria Michael
OBOlga Benopoulou
Olga Benopoulou
EBEfthymia Bazanis
Efthymia Bazanis
GTGeorge Tzeletas
George Tzeletas
NVNora-Athina Viniou
Nora-Athina Viniou
Myelodysplastic syndromes (MDS) are often accompanied by autoimmune phenomena. The underlying mechanisms for these associations remain uncertain, although T cell activation seems to be important. Human T-lymphotropic virus (HTLV-1) has been detected in patients with myelodysplastic syndromes, mostly in regions of the world which are endemic for the virus, and where association of HTLV-1 with rheumatological manifestation is not rare. We present here the case of a 58 year old man who presented with cytopenias, leukocytoclastic vasculitis of the skin and glomerulopathy, and was diagnosed as MDS (refractory anemia with excess blasts - RAEB 1). The patient also tested positive for HTLV-1 by PCR. After 8 monthly cycles of 5-azacytidine he achieved a complete hematologic remission. Following treatment, a second PCR for HTLV-1 was carried out and found to be negative. This is the first report in the literature of a HTLV-1-positive MDS with severe autoimmune manifestations, which was treated with the hypomethylating factor 5-azacitidine, achieving cytogenetic remission with concomitant resolution of the autoimmune manifestations, as well as HTLV-1-PCR negativity. HTLV-1-PCR negativity may be due to either immune mediated clearance of the virus, or a potential antiretroviral effect of 5-azacytidine. 5-azacytidine is known for its antiretroviral effects, although there is no proof of its activity against HTLV-1 infection in vivo.

22 December 2003 in European Journal of Haematology
Verified
Journal Article
Closed access
PDF file
NVNora‐Athina Viniou
Nora‐Athina Viniou
Theodoros VassilakopoulosTheodoros Vassilakopoulos
Theodoros Vassilakopoulos
XGXanthi Giakoumi
Xanthi Giakoumi
MMMarina Mantzouranis
Marina Mantzouranis
GPGerassimos A. Pangalis
Gerassimos A. Pangalis

5 January 2021 in Diagnostics
Verified
Journal Article
Open access
PDF file
MBMaria Bonou
Maria Bonou
Sophie I. MavrogeniSophie I. Mavrogeni
Sophie I. Mavrogeni
Chris KapeliosChris Kapelios
Chris Kapelios
MSMarina Skouloudi
Marina Skouloudi
CAConstantina Aggeli
Constantina Aggeli
JBJohn Barbetseas
John Barbetseas
Cardiovascular (CV) complications represent the first non-graft-related cause of death and the third overall cause of death among patients undergoing liver transplantation (LT). History of coronary artery disease is related to increased CV mortality following LT. Although it is of paramount importance to stratify CV risk in pre-LT patients, there is no consensus regarding the choice of the optimal non-invasive cardiac imaging test. Algorithms proposed by scientific associations include non-traditional risk factors, which are associated with increased cardiac risk profiles. Thus, an individualized pre-LT evaluation protocol should be followed. As the average age of patients undergoing LT and the number of candidates continue to rise, the “3 W” questions still remain unanswered, Who, Which and When? Who should be screened for coronary artery disease (CAD), which screening modality should be used and when should the asymptomatic waitlisted patients repeat cardiac evaluation? Prospective studies with large sample sizes are warranted to define an algorithm that can provide better risk stratification and more reliable survival prediction.

1 March 2019 in BMC Cancer
Verified
Journal Article
Open access
PDF file
MBMaria Bonou
Maria Bonou
Chris KapeliosChris Kapelios
Chris Kapelios
AMAthanasios Marinakos
Athanasios Marinakos
SAStamatis Adamopoulos
Stamatis Adamopoulos
PDPanagiotis Theodorou Diamantopoulos
Panagiotis Theodorou Diamantopoulos
NVNora-Athina Viniou
Nora-Athina Viniou
Primary cardiac lymphomas (PCL) represent extremely rare cardiac tumors which are accompanied by poor prognosis, unless they are timely diagnosed and treated. Herein we present a 28-year-old, immunocompetent man who presented to our hospital due to progressively worsening symptoms and signs of superior vena cava syndrome. Multi-modality imaging demonstrated a large intracardiac tumor, which was proven, by biopsy, to be a PCL. The patient received targeted chemotherapy which led to total remission of his disease, with no relapse over a 15-month follow-up period. Although PCLs are rare, they should always be kept in mind in the differential diagnosis of cardiac tumors. Timely diagnosis of PCLs and appropriate chemotherapy, alone or in combination with radiotherapy, seems to provide the best results.

20 February 2021 in Diagnostics
Verified
Journal Article
Open access
PDF file
MBMaria Bonou
Maria Bonou
Sophie I. MavrogeniSophie I. Mavrogeni
Sophie I. Mavrogeni
Chris KapeliosChris Kapelios
Chris Kapelios
GMGeorge Markousis-Mavrogenis
George Markousis-Mavrogenis
CAConstantina Aggeli
Constantina Aggeli
JBJohn Barbetseas
John Barbetseas
Increased cardiac fat depots are metabolically active tissues that have a pronounced pro-inflammatory nature. Increasing evidence supports a potential role of cardiac adiposity as a determinant of the substrate of atrial fibrillation and ventricular arrhythmias. The underlying mechanism appears to be multifactorial with local inflammation, fibrosis, adipocyte infiltration, electrical remodeling, autonomic nervous system modulation, oxidative stress and gene expression playing interrelating roles. Current imaging modalities, such as echocardiography, computed tomography and cardiac magnetic resonance, have provided valuable insight into the relationship between cardiac adiposity and arrhythmogenesis, in order to better understand the pathophysiology and improve risk prediction of the patients, over the presence of obesity and traditional risk factors. However, at present, given the insufficient data for the additive value of imaging biomarkers on commonly used risk algorithms, the use of different screening modalities currently is indicated for personalized risk stratification and prognostication in this setting.

1 May 2002 in Acta Haematologica
Verified
Journal Article
Closed access
PDF file
NVNora Viniou
Nora Viniou
EPEleni Plata
Eleni Plata
ETEvangelos Terpos
Evangelos Terpos
EVEleni Variami
Eleni Variami
JMJohn Meletis
John Meletis
XYXenophon Yataganas
Xenophon Yataganas